Apotex Asks DC Circ. To Stay Teva's Hyzaar Exclusivity

Law360, New York (April 6, 2010, 4:05 PM EDT) -- Apotex Inc. has asked a federal appeals court to bar Teva Pharmaceuticals USA Inc. from gaining a 180-day exclusivity period on generic versions of Merck & Co. Inc. hypertension drugs Hyzaar and Cozaar.

Apotex filed an emergency motion in the U.S. Court of Appeals for the District of Columbia Circuit on Monday, seeking a stay of the U.S. Food and Drug Administration's award of exclusivity to Teva, as well as a stay on approval of all abbreviated new drug applications related to the drugs.

The FDA...
To view the full article, register now.